With a consistent 4.1% CAGR from 2022 to 2032, the rare sugar market is anticipated to surpass USD 1.5 billion in 2022 and reach USD 2.1 billion by 2032. The global population is ...
The company utilizes the Multiclonics, Biclonics and Triclonics platforms to develop human bispecific and tri-specific antibodies. Its pipeline products include petosemtamab (MCLA-158), a low-fucose ...